Azathioprine as an adjuvant therapy in severe Graves’ disease: a randomized controlled open-label clinical trial
Magdy Mohamed Allam, Hanaa Tarek El-Zawawy, Amr Abdel Kader Okda, Ayoub Ali Alshaikh and Ramy Mohamed Ghazy Introduction: Azathioprine (AZA) interferes with the activation of T and B lymphocytes, which are the main cells involved in the pathogenesis of Graves’ disease (GD). The aim of this study was to investigate the effectiveness of AZA as an […]










